These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8182985)

  • 1. [The beneficial effect of 1,25-dihydroxycholecalciferol on the excess of blasts and the myelofibrosis in 2 cases of chronic myeloproliferative syndrome].
    Raya Sánchez JM; Hernández Nieto L; Brito Barroso ML; Hernández García MT
    Med Clin (Barc); 1994 Mar; 102(10):380-2. PubMed ID: 8182985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Beneficial effect of 1,25-dihydroxyvitamin D3 in the treatment of myelofibrosis].
    Palomera L; García Díez I; Martínez R
    Med Clin (Barc); 1989 Sep; 93(7):265-8. PubMed ID: 2811498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro culture techniques defining biological abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Clin Haematol; 1986 Nov; 15(4):973-93. PubMed ID: 3552351
    [No Abstract]   [Full Text] [Related]  

  • 5. [Is 1,25(OH)2D3 effective in chronic osteomyelofibrosis?].
    Eugster C; Brun del Re GP; Bucher U
    Schweiz Med Wochenschr; 1986 Dec; 116(50):1767-70. PubMed ID: 3798067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelofibrosis in the myeloproliferative disorders.
    Ellis JT; Peterson P
    Prog Clin Biol Res; 1984; 154():19-42. PubMed ID: 6382293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myeloproliferative diseases].
    Verh Dtsch Ges Pathol; 1983; 67():214-75. PubMed ID: 6666266
    [No Abstract]   [Full Text] [Related]  

  • 11. [Onset of polycythemia in idiopathic myelofibrosis. Description of a clinical case and review of the literature].
    Pagano L; Teofili L; Marra R; Storti S; Rabbitti C; Leone G; Bizzi B
    Minerva Med; 1988 Jan; 79(1):51-4. PubMed ID: 3277085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
    Thiele J; Kvasnicka HM; Vardiman J
    Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?
    Ohyashiki K; Yokoyama K; Kimura Y; Ohyashiki JH; Ito T; Kuratsuji T; Komatsumoto S; Nara M; Toyama K
    Leukemia; 1993 Feb; 7(2):338-40. PubMed ID: 8426488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM; Thiele J
    Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case].
    Uemura Y; Iwahara Y; Kataoka R; Muneishi H; Miyoshi I
    Rinsho Ketsueki; 1990 Sep; 31(9):1553-6. PubMed ID: 2246832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myelofibrosis with peripheral myeloblastosis: an acute myeloproliferative disorder.
    Spector JI; Miller S
    Arch Pathol Lab Med; 1978 Nov; 102(11):564-6. PubMed ID: 581448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of myelofibrosis that developed polycythemia vera following treatment with ranimustine and then acute myelogenous leukemia (M0)].
    Harashima S; Okamura T; Umeno M; Takaki K
    Rinsho Ketsueki; 1996 Aug; 37(8):713-8. PubMed ID: 8827883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrastructural characteristics of bone marrow in patients with hematological disease: a study of 13 cases.
    Ru YX; Zhao SX; Liu EB; Yang QY; Liu JH; Pang TX; Chen HS
    Ultrastruct Pathol; 2007; 31(5):327-32. PubMed ID: 17963181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma with bone marrow biopsy features simulating concomitant chronic idiopathic myelofibrosis.
    Schmidt U; Ruwe M; Leder LD
    Nouv Rev Fr Hematol (1978); 1995; 37(2):159-63. PubMed ID: 7644355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.